<DOC>
	<DOC>NCT00050596</DOC>
	<brief_summary>The primary objectives of the study are to determine the safety and activity of multiple doses of MDX-010 in patients with hormone-refractory prostate cancer (HRPC), and to determine the safety and activity profile of a single dose of cytotoxic chemotherapy (docetaxel) in combination with MDX-010</brief_summary>
	<brief_title>Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Clinical diagnosis of adenocarcinoma of the prostate. Metastatic prostate cancer (positive bone scan or measurable disease). Progressive disease after androgen deprivation. No prior chemotherapy or immunotherapy (tumor vaccine, cytokine, or growth factor given to control prostate cancer). Other prior malignancy, except for adequately treated basal or squamous cell skin cancer or superficial bladder cancer, or any other cancer from which the patient has been diseasefree for greater than or equal to 5 years. Previous occurrence of autoimmune disease. Active infection requiring therapy including HIV or chronic hepatitis.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>